GILD Stock Gilead Sciences (GILD, $125.2) Moving Average Convergence Divergence (MACD) Histogram turned positive on November 13, 2025

GET DAILY SIGNALS

Get AI intraday signals

GILD - Gilead Sciences

MACD signal

View

Odds of UP Trend

Price: $125.2

Daily change: +$1.8 (+1.46%)

Daily volume: 9.3M

Capitalization: $155.3B

Industry: Pharmaceuticals: Major

This is a Bullish indicator signaling GILD's price could rise from here. Traders may explore going long the stock or buying call options. A.I. dvisor identified 57 similar cases where GILD's MACD histogram became positive, and of them led to successful outcomes. Odds of Success:

GILD's Stochastic Oscillator stays in oversold zone for 1 day

Be on the lookout for a price bounce soon.

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GILD advanced for three days, in of 329 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 288 cases where GILD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 01, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on GILD as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for GILD turned negative on December 01, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 58 similar instances when the indicator turned negative. In of the 58 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GILD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 75, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.199) is normal, around the industry mean (8.946). P/E Ratio (19.350) is within average values for comparable stocks, (24.032). Projected Growth (PEG Ratio) (0.228) is also within normal values, averaging (2.044). Dividend Yield (0.025) settles around the average of (0.027) among similar stocks. P/S Ratio (5.423) is also within normal values, averaging (3.663).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. GILD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.